Cdc42 Inhibition Platform (CASIN)
Multiple age-related diseases (e.g., Osteoporosis, Immunosenescence, Neurodegeneration)
Pre-clinicalActive
Key Facts
Indication
Multiple age-related diseases (e.g., Osteoporosis, Immunosenescence, Neurodegeneration)
Phase
Pre-clinical
Status
Active
Company
About Mogling Bio
Mogling Bio is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, USA, targeting the biology of aging. The company's core technology platform focuses on inhibiting the age-associated overactivation of the Cdc42 GTPase protein to rejuvenate stem cell function and combat a range of age-related conditions. Backed by seed investment from Kizoo Technology Capital and an exclusive license for its lead asset CASIN from Cincinnati Children's Hospital, Mogling Bio is positioned at the intersection of aging biology and regenerative medicine. Its approach has the potential to create a new class of therapeutics for degenerative diseases.
View full company profile